1. Medtech Insight

Pear Therapeutics Adds Two PDTs To Treat Depression

 
• By Reed Miller

Pear Therapeutics acquired a digital therapeutic for depression from Waypoint Health and licensed an Internet-based cognitive behavior therapy program for residual symptoms of depression from a psychologist in Sweden.

• Source: Alamy

Pear Therapeutics is adding depression to the growing list of conditions addressed by its cognitive behavioral therapy (CBT) prescription digital therapeutic (PDTs) technology.

A recent study, led by Catherine Ettman of Boston University, showed that about a third of US adults experienced depressive symptoms in 2021, compared to 28% of adults in 2020, and 8.5% before the pandemic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from Medtech Insight

Beyond The Bladder: Incontinence Impacts Mental Health

 
• By Brian Bossetta

In recognition of Mental Health Awareness month, Sarah Jenkins, executive director at the National Association for Continence, discussed the mental health issues that often come with incontinence.

AI Rollout Aims To Accelerate FDA’s Product Review Process

 
• By Elizabeth Orr

The FDA plans to implement artificial intelligence in its scientific review process by 30 June, following a successful pilot. The agency hopes the tool will reduce nonproductive tasks for reviewers amid recent staff cuts. A Chief AI Officer will oversee the rollout and integration.

Access To Library Tools Being Restored At US FDA

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals and laid off librarians have not been reinstated.